Enhancement of alkylating agent activity by SR-4233 in the FSaIIC muraine fibrosarcoma

Journal of the National Cancer Institute

Volumn 84, Issue 3, 1992, Pages 187-193

  Holden, Sylvia A ^a   Teicher, Beverly A ^a   Ara, Gulshan ^a   Herman, Terence S ^a   Coleman, C Norman ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; HOE 33342; MELPHALAN; TIRAPAZAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL KILLING; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; FIBROSARCOMA; HYPOXIC CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH;

ALKYLATING AGENTS; ANIMAL; ANTINEOPLASTIC AGENTS; BONE MARROW; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FIBROSARCOMA; MALE; MELPHALAN; MICE; MICE, INBRED C3H; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRIAZINES;

EID: 0026513038     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/84.3.187     Document Type: Article

References (39)

1. Rose CM, Millar JL, Peacock JH, et al: Differential enhancement of melphalan cytotoxicity in tumors and normal tissue by misonidazole. In Radiation Sensitizers: Their Use in the Clinical Management of Cancer (Brady LW, ed). New York: Masson, 1980, pp 250–257
2. Clement JJ, Gorman MS, Wodinsky I, et al: Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. Cancer Res 40:4165–4172, 1980
3. Fowler JF: Eighth annual Juan del Regato lecture. Chemical modifiers of radiosensitivity-theory and reality: A review. Int J Radiat Oncol Biol Phys 11:665–674, 1985
4. Grau C, Zachariae C, Mao HS, et al: The in vivo response of a C3H mammary carcinoma to treatment with misonidazole, cyclophosphamide and radiation. Acta Oncol 29:769–774, 1990
5. Coleman CN, Carlson RW, Artim RA, et al: Enhancement of the clinical activity of melphalan by the hypoxic cell sensitizer misonidazole. Cancer Res 48:3528–3532, 1988
6. Kohn KW: Molecular mechanisms of cross-linking by alkylating agents and platinum complexes. In Molecular Actions and Targets for Cancer Chemotherapeutic Agents (Sartorelli AC, Lazo JS, Bertino JR, eds). New York: Academic Press, 1981, pp 3–16
7. Zwelling LA, Michaels S, Schwartz H, et al: DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum(II) and L-phenylalanine mustard. Cancer Res 41:640–649, 1981
8. Murray D, Meyn RE: Enhancement of the DNA cross-linking activity of melphalan by misonidazole in vivo. Br J Cancer 47:195–203, 1983
9. Taylor YC, Evans JW, Brown JM: Mechanism of sensitization of Chinese hamster ovary cells to melphalan by hypoxic treatment with misonidazole. Cancer Res 43:3175–3181, 1983
10. Horsman MR, Evans JW, Brown JM: Enhancement of melphalan-induced tumor cell killing by misonidazole: An interaction of competing mechanisms. Br J Cancer 50:305–316, 1984
11. Randhawa VS, Stewart FA, Denekamp J, et al: Factors influencing the chemosensitization of melphalan by misonidazole. Br J Cancer 51:219–228, 1985
12. Workman P, Twentyman PR, Lee FYF, et al: Drug metabolism and chemosensitization: Nitroimidazoles as inhibitors of drug metabolism. Biochem Pharmacol 32:857–864, 1983
13. Lee FY, Workman P: Misonidazole and CCNU: Further evidence for a pharmacokinetic mechanism of chemosensitization and therapeutic gain. Br J Cancer 49:579–585, 1984
14. Begleiter A, Grover J, Froese E, et al: Membrane transport, sulfhydryl levels and DNA cross-linking in Chinese hamster ovary cell mutants sensitive and resistant to melphalan. Biochem Pharmacol 32:293–300, 1983
15. Zeman EM, Hirst VK, Lemmon MJ, et al: Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother Oncol 12:209–218, 1988
16. Zeman EM, Brown JM: Pre- and post-irradiation radiosensitization by SR 4233. Int J Radiat Oncol Biol Phys 16:967–971, 1989
17. Zeman EM, Baker MA, Lemmon MJ, et al: Structure-activity relationships for benzotria- zine di-iV-oxides. Int J Radiat Oncol Biol Phys 16:977–981, 1989
18. Sun JR, Brown JM: Enhancement of the anti-tumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma. Cancer Res 49:5664–5670, 1989
19. Laderoute K, Wardman P, Rauth AM: Molecular mechanisms for the hypoxia-dependent activation of 3-ammo-l, 2, 4-benzotriazine-l, 4-dioxide (SR 4233). Biochem Pharmacol 37:1487–1495, 1988
20. Baker MA, Zeman EM, Hirst VK, et al: Metabolism of SR 4233 by Chinese hamster ovary cells: Basis of selective hypoxic cytotoxicity. Cancer Res 48:5947–5952, 1988
21. Costa AK, Baker MA, Brown JM, et al: In vitro hepatotoxicity of SR 4233 (3-amino- 1, 2, 4-benzotriazine-1, 4-dioxide), a hypoxic cytotoxin and potential antitumor agent. Cancer Res 49:925–929, 1989
22. Herman TS, Teicher BA, Coleman CN: Interaction of SR-4233 with hyperthermia and radiation in the FSallC murine fibrosarcoma tumor system in vitro and in vivo. Cancer Res 50:5055–5059, 1990
23. Brown JM, Lemmon MJ: Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50:7745–7749, 1990
24. Walton MI, Workman P: Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochem Pharmacol 39:1735–1742, 1990
25. Biedermann KA, Brown JM: Comparison between x-rays and SR 4233 for cytotoxicity and repair of potentially lethal damage in human cells. Int J Radiat Biol 56:813–816, 1989
26. Zeman EM, Lemmon MJ, Brown JM: Aerobic radiosensitization by SR 4233 in vitro and in vivo. Int J Radiat Oncol Biol Phys 18:125–132, 1990
27. Rice L, Urano M, Suit HD: The radiosensitivity of a murine fibrosarcoma as measured by three cell survival assays. Br J Cancer Suppl 41:240–245, 1980
28. Teicher BA, Rose CM: Perfluorochemical emulsions can increase tumor radiosensitivity. Science 223:934–936, 1984
29. Teicher BA, Holden SA, Jacobs JL: Approaches to defining the mechanism of Fluosol-DA 20% with carbogen of melphalan antitumor activity. Cancer Res 47:513–518, 1987
30. Siemann DW, Keng PC: Characterization of radiation resistant hypoxic cell subpopulations in KHT sarcomas. II. Cell sorting. Br J Cancer 58:296–300, 1988
31. Teicher BA, Holden SA, Al-Achi A, et al: Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 50:3339–3344, 1990
32. Chaplin DJ, Durand RE, Olive PL: Cell selection from a murine tumour using the fluorescent probe Hoechst 33342. Br J Cancer 51:569–572, 1985
33. Deen DF, Williams ME: Isobologram analysis of x-ray-BCNU interactions in vitro, Radiat Res 79:483–491, 1977
34. Berenbaum MC: Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol 28:1–18, 1977
35. Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemother- apy: The concept of additivity. Int J Radiat Oncol Biol Phys 5:85–91, 1979
36. Teicher BA, Holden SA, Cucchi CA, et al: Combination of N, N′. N′′-rriethylenethio-phosphoramide and cyclophosphamide in vitro and in vivo. Cancer Res 48:94–100, 1988
37. Frej E III, Teicher BA, Holden SA, et al: Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 48:6417–6423, 1988
38. Sartorelli AC: Therapeutic attack of hypoxic cells of solid tumors: Presidential address. Cancer Res 48:775–778, 1988
39. Coleman CN: Hypoxia in tumors: A paradigm for the approach to biochemical and physiologic heterogeneity. J Natl Cancer Inst 80:310–317, 1988